A detailed history of Trexquant Investment LP transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 149,418 shares of TGTX stock, worth $3.56 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
149,418
Holding current value
$3.56 Million
% of portfolio
0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$13.32 - $19.19 $1.99 Million - $2.87 Million
149,418 New
149,418 $2.66 Million
Q4 2023

Feb 09, 2024

SELL
$6.68 - $18.81 $269,130 - $757,836
-40,289 Reduced 10.32%
350,218 $5.98 Million
Q3 2023

Nov 13, 2023

BUY
$8.36 - $26.5 $2.06 Million - $6.52 Million
246,022 Added 170.28%
390,507 $3.26 Million
Q2 2023

Aug 11, 2023

BUY
$15.48 - $35.0 $2.24 Million - $5.06 Million
144,485 New
144,485 $3.59 Million
Q4 2022

Feb 13, 2023

BUY
$5.01 - $11.83 $1.76 Million - $4.15 Million
351,098 Added 992.67%
386,467 $4.57 Million
Q3 2022

Nov 14, 2022

BUY
$4.57 - $8.4 $161,636 - $297,099
35,369 New
35,369 $209,000
Q1 2020

May 08, 2020

SELL
$7.14 - $15.99 $296,467 - $663,936
-41,522 Closed
0 $0
Q4 2019

Feb 12, 2020

BUY
$5.1 - $11.2 $211,762 - $465,046
41,522 New
41,522 $461,000
Q3 2018

Nov 09, 2018

SELL
$5.15 - $14.0 $110,838 - $301,308
-21,522 Closed
0 $0
Q2 2018

Aug 07, 2018

SELL
$12.5 - $15.0 $805,262 - $966,315
-64,421 Reduced 74.96%
21,522 $283,000
Q1 2018

May 03, 2018

BUY
$8.7 - $16.8 $162,690 - $314,160
18,700 Added 27.81%
85,943 $1.22 Million
Q4 2017

Feb 09, 2018

BUY
$7.35 - $12.3 $494,236 - $827,088
67,243
67,243 $551,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $3.46B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.